BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37319432)

  • 1. A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma.
    Merrill MH; Dahi PB; Redd RA; McDonough MM; Chen YB; DeFilipp Z; Herrera AF; Fisher DC; LaCasce AS; Odejide OO; Ng SY; Jacobson CA; Merryman RW; Kim AI; Nieto YL; Sauter CS; Shah GL; Zain JM; Armand P; Jacobsen ED
    Blood; 2023 Aug; 142(7):621-628. PubMed ID: 37319432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.
    Armand P; Chen YB; Redd RA; Joyce RM; Bsat J; Jeter E; Merryman RW; Coleman KC; Dahi PB; Nieto Y; LaCasce AS; Fisher DC; Ng SY; Odejide OO; Freedman AS; Kim AI; Crombie JL; Jacobson CA; Jacobsen ED; Wong JL; Patel SS; Ritz J; Rodig SJ; Shipp MA; Herrera AF
    Blood; 2019 Jul; 134(1):22-29. PubMed ID: 30952672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.
    Merryman RW; Redd R; Jeter E; Wong JL; McHugh K; Reynolds C; Nazzaro M; Varden A; Brown JR; Crombie JL; Davids MS; Fisher DC; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Ng SY; Odejide OO; Parry EM; Dahi PB; Nieto Y; Joyce RM; Chen YB; Herrera AF; Armand P; Ritz J
    Transplant Cell Ther; 2022 Jan; 28(1):32.e1-32.e10. PubMed ID: 34670169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation.
    Frigault MJ; Armand P; Redd RA; Jeter E; Merryman RW; Coleman KC; Herrera AF; Dahi P; Nieto Y; LaCasce AS; Fisher DC; Ng SY; Odejide OO; Freedman AS; Kim AI; Crombie JL; Jacobson CA; Jacobsen ED; Wong JL; Bsat J; Patel SS; Ritz J; Rodig SJ; Shipp MA; Chen YB; Joyce RM
    Blood Adv; 2020 Jan; 4(1):122-126. PubMed ID: 31917843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404).
    Cho H; Yoon DH; Shin DY; Koh Y; Yoon SS; Kim SJ; Do YR; Lee GW; Kwak JY; Park Y; Kim MK; Kang HJ; Yi JH; Yoo KH; Lee WS; Park BB; Jo JC; Eom HS; Kim HJ; Jeong SH; Won YW; Sohn BS; Kwon JH; Suh C; Kim WS
    Cancer Res Treat; 2023 Apr; 55(2):684-692. PubMed ID: 36596727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
    Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Shustov AR;
    Cancer; 2019 May; 125(9):1507-1517. PubMed ID: 30694529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
    d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Österborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Østenstad B; Fagerli UM; Gadeberg OV; Sundström C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE
    J Clin Oncol; 2012 Sep; 30(25):3093-9. PubMed ID: 22851556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-front autologous stem cell transplant in peripheral T-cell lymphoma patients achieving complete response after first-line treatment: A multicentre real-world analysis.
    Yang P; Cai M; Cao Y; Fan S; Tang W; Ji M; Huang L; Wang F; Zhao W; Niu T; Mo X
    Br J Haematol; 2024 Apr; 204(4):1414-1421. PubMed ID: 38272453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas.
    Yam C; Landsburg DJ; Nead KT; Lin X; Mato AR; Svoboda J; Loren AW; Frey NV; Stadtmauer EA; Porter DL; Schuster SJ; Nasta SD
    Am J Hematol; 2016 Jul; 91(7):672-6. PubMed ID: 27012928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study.
    García-Sancho AM; Bellei M; López-Parra M; Gritti G; Cortés M; Novelli S; Panizo C; Petrucci L; Gutiérrez A; Dlouhy I; Bastos-Oreiro M; Sancho JM; Ramírez MJ; Moraleda JM; Carrillo E; Jiménez-Ubieto AI; Jarque I; Orsucci L; García-Torres E; Montalbán C; Dodero A; Arranz R; De Las Heras N; Pascual MJ; López-Jiménez J; Spina M; Re A; De Villambrosia SG; Bobillo S; Federico M; Caballero D
    Haematologica; 2022 Nov; 107(11):2675-2684. PubMed ID: 35320921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
    Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C
    Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HEMATOPOIETIC STEM CELL TRANSPLANT IN AGGRESSIVE T AND NK/T CELL LYMPHOMA - ROLE OF UPFRONT AUTOLOGOUS TRANSPLANT IN NODAL PERIPHERAL T-CELL LYMPHOMA.
    Cheng Kiat Ng L; Shwei Wen Tham C; Wei Inng Lim F; Chen Y; Yeu Ong S; Nagarajan C; Lee JJ; Tee Goh Y; Linn YC; Shan Lee Y; Diong Phipps C; Kim Siang Quek J; Hein T; Cheng Hwang JC; Grigoropoulos N; Khee Hwang WY; Yew Leng Ho A
    Blood Cell Ther; 2021 Nov; 4(4):92-100. PubMed ID: 36714065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
    Gkotzamanidou M; Papadimitriou CA
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial.
    Ladetto M; Tavarozzi R; Zanni M; Evangelista A; Ferrero S; Tucci A; Botto B; Bolis S; Volpetti S; Zilioli VR; Puccini B; Arcari A; Pavone V; Gaidano G; Corradini P; Tani M; Cavallo F; Milone G; Ghiggi C; Pinto A; Pastore D; Ferreri AJM; Latte G; Patti C; Re F; Benedetti F; Luminari S; Pennese E; Bossi E; Boccomini C; Anastasia A; Bottelli C; Ciccone G; Vitolo U
    Ann Oncol; 2024 Jan; 35(1):118-129. PubMed ID: 37922989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience.
    Han X; Zhang W; Zhou D; Ruan J; Duan M; Zhu T; Li J; Cai H; Cao X; Ouyang M
    J Int Med Res; 2017 Feb; 45(1):290-302. PubMed ID: 28222648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of autologous stem cell transplantation on survival outcomes in patients with peripheral T cell lymphoma.
    Guren CU; Toptas T; Mehtap O; Yılmaz G; Polat G; Oruc O; Ercan T; Arikan F; Yilmaz F; Atagunduz IK; Tuglular T
    Transfus Apher Sci; 2022 Dec; 61(6):103514. PubMed ID: 35934613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficiency of autologous stem cell transplantation as the first-line treatment for nodal peripheral T-cell lymphoma: results of a systematic review and meta-analysis.
    Zhai Y; Wang J; Jiang Y; Wu W; Lv Y; Xu H; Tian L; Sun H; Zhao Z; Li L
    Expert Rev Hematol; 2022 Mar; 15(3):265-272. PubMed ID: 35152814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.